BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 36269819)

  • 21. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.
    Gröschel S; Schlenk RF; Engelmann J; Rockova V; Teleanu V; Kühn MW; Eiwen K; Erpelinck C; Havermans M; Lübbert M; Germing U; Schmidt-Wolf IG; Beverloo HB; Schuurhuis GJ; Ossenkoppele GJ; Schlegelberger B; Verdonck LF; Vellenga E; Verhoef G; Vandenberghe P; Pabst T; Bargetzi M; Krauter J; Ganser A; Valk PJ; Löwenberg B; Döhner K; Döhner H; Delwel R
    J Clin Oncol; 2013 Jan; 31(1):95-103. PubMed ID: 23008312
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low expression of MDS1-EVI1-like-1 (MEL1) and EVI1-like-1 (EL1) genes in favorable-risk acute myeloid leukemia.
    Barjesteh van Waalwijk van Doorn-Khosrovani S; Erpelinck C; Löwenberg B; Delwel R
    Exp Hematol; 2003 Nov; 31(11):1066-72. PubMed ID: 14585371
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aberrant expression of ecotropic viral integration site-1 in acute myeloid leukemia and acute lymphoblastic leukemia.
    Su G; Lian X; Tan D; Tao H; Liu H; Chen S; Yin H; Wu D; Yin B
    Leuk Lymphoma; 2015 Feb; 56(2):472-9. PubMed ID: 24828867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs.
    Bindels EM; Havermans M; Lugthart S; Erpelinck C; Wocjtowicz E; Krivtsov AV; Rombouts E; Armstrong SA; Taskesen E; Haanstra JR; Beverloo HB; Döhner H; Hudson WA; Kersey JH; Delwel R; Kumar AR
    Blood; 2012 Jun; 119(24):5838-49. PubMed ID: 22553314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription.
    Maicas M; Vázquez I; Vicente C; García-Sánchez MA; Marcotegui N; Urquiza L; Calasanz MJ; Odero MD
    Oncogene; 2013 Apr; 32(16):2069-78. PubMed ID: 22689058
    [TBL] [Abstract][Full Text] [Related]  

  • 26. All-trans retinoic acid enhances, and a pan-RAR antagonist counteracts, the stem cell promoting activity of EVI1 in acute myeloid leukemia.
    Nguyen CH; Bauer K; Hackl H; Schlerka A; Koller E; Hladik A; Stoiber D; Zuber J; Staber PB; Hoelbl-Kovacic A; Purton LE; Grebien F; Wieser R
    Cell Death Dis; 2019 Dec; 10(12):944. PubMed ID: 31822659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Global Identification of EVI1 Target Genes in Acute Myeloid Leukemia.
    Glass C; Wuertzer C; Cui X; Bi Y; Davuluri R; Xiao YY; Wilson M; Owens K; Zhang Y; Perkins A
    PLoS One; 2013; 8(6):e67134. PubMed ID: 23826213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EVI1 abrogates interferon-alpha response by selectively blocking PML induction.
    Buonamici S; Li D; Mikhail FM; Sassano A; Platanias LC; Colamonici O; Anastasi J; Nucifora G
    J Biol Chem; 2005 Jan; 280(1):428-36. PubMed ID: 15519999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.
    Barjesteh van Waalwijk van Doorn-Khosrovani S; Erpelinck C; van Putten WL; Valk PJ; van der Poel-van de Luytgaarde S; Hack R; Slater R; Smit EM; Beverloo HB; Verhoef G; Verdonck LF; Ossenkoppele GJ; Sonneveld P; de Greef GE; Löwenberg B; Delwel R
    Blood; 2003 Feb; 101(3):837-45. PubMed ID: 12393383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia.
    Balgobind BV; Lugthart S; Hollink IH; Arentsen-Peters ST; van Wering ER; de Graaf SS; Reinhardt D; Creutzig U; Kaspers GJ; de Bont ES; Stary J; Trka J; Zimmermann M; Beverloo HB; Pieters R; Delwel R; Zwaan CM; van den Heuvel-Eibrink MM
    Leukemia; 2010 May; 24(5):942-9. PubMed ID: 20357826
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice.
    Cuenco GM; Ren R
    Oncogene; 2004 Jan; 23(2):569-79. PubMed ID: 14724585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiopoietin1 contributes to the maintenance of cell quiescence in EVI1(high) leukemia cells.
    Ichihara E; Kaneda K; Saito Y; Yamakawa N; Morishita K
    Biochem Biophys Res Commun; 2011 Dec; 416(3-4):239-45. PubMed ID: 22033412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The adverse impact of ecotropic viral integration site-1 (EVI1) overexpression on the prognosis of acute myeloid leukemia with KMT2A gene rearrangement in different risk stratification subtypes.
    Liu XX; Pan XA; Gao MG; Kong J; Jiang H; Chang YJ; Zhang XH; Wang Y; Liu KY; Chen Z; Zhao XS; Huang XJ
    Int J Lab Hematol; 2023 Apr; 45(2):195-203. PubMed ID: 36358022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The role of SF3B1 mutations in EVI1-rearranged myeloid neoplasms].
    Tanaka A
    Rinsho Ketsueki; 2023; 64(10):1258-1265. PubMed ID: 37914237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The oncogene EVI1 enhances transcriptional and biological responses of human myeloid cells to all-trans retinoic acid.
    Steinmetz B; Hackl H; Slabáková E; Schwarzinger I; Smějová M; Spittler A; Arbesu I; Shehata M; Souček K; Wieser R
    Cell Cycle; 2014; 13(18):2931-43. PubMed ID: 25486480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EVI1 gene and is transcriptionally activated in t(1;3)(p36;q21)-positive leukemia cells.
    Mochizuki N; Shimizu S; Nagasawa T; Tanaka H; Taniwaki M; Yokota J; Morishita K
    Blood; 2000 Nov; 96(9):3209-14. PubMed ID: 11050005
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.
    Lugthart S; van Drunen E; van Norden Y; van Hoven A; Erpelinck CA; Valk PJ; Beverloo HB; Löwenberg B; Delwel R
    Blood; 2008 Apr; 111(8):4329-37. PubMed ID: 18272813
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EVI1 triggers metabolic reprogramming associated with leukemogenesis and increases sensitivity to L-asparaginase.
    Saito Y; Sawa D; Kinoshita M; Yamada A; Kamimura S; Suekane A; Ogoh H; Matsuo H; Adachi S; Taga T; Tomizawa D; Osato M; Soga T; Morishita K; Moritake H
    Haematologica; 2020 Aug; 105(8):2118-2129. PubMed ID: 31649131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional features of EVI1 and EVI1Δ324 isoforms of MECOM gene in genome-wide transcription regulation and oncogenicity.
    Sayadi A; Jeyakani J; Seet SH; Wei CL; Bourque G; Bard FA; Jenkins NA; Copeland NG; Bard-Chapeau EA
    Oncogene; 2016 May; 35(18):2311-21. PubMed ID: 26234679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia.
    Tanaka A; Nakano TA; Nomura M; Yamazaki H; Bewersdorf JP; Mulet-Lazaro R; Hogg S; Liu B; Penson A; Yokoyama A; Zang W; Havermans M; Koizumi M; Hayashi Y; Cho H; Kanai A; Lee SC; Xiao M; Koike Y; Zhang Y; Fukumoto M; Aoyama Y; Konuma T; Kunimoto H; Inaba T; Nakajima H; Honda H; Kawamoto H; Delwel R; Abdel-Wahab O; Inoue D
    Blood; 2022 Aug; 140(8):875-888. PubMed ID: 35709354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.